EPHA5 and metastatic malignant neoplasm: Analysis of a few patients with metastatic cancer survive exceptionally longer than others under the same treatment identified multiple common mutations of NOTCH2, NF1, FANCD2, PIK3CB and EPHA5 in tumors that responded exceptionally well to treatments [42].